Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial
Rituparna Das, Daniel Blázquez‐Gamero, David I. Bernstein, Soren Gantt, Oliver Bautista, Karen Beck, Anthony Conlon, Daniel I. S. Rosenbloom, Dai Wang, Michael Ritter, Beth Arnold, Paula W. Annunziato, Kevin L. Russell
Topics & Concepts
MedicineRegimenPlaceboTolerabilityClinical endpointPopulationRandomized controlled trialIncidence (geometry)Internal medicineAdverse effectPediatricsCytomegalovirusImmunologyViral diseaseHuman immunodeficiency virus (HIV)HerpesviridaePhysicsPathologyOpticsAlternative medicineEnvironmental healthCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsViral Infections and Immunology Research